Hester Biosciences Limited has corrected the gross salary for Executive Director Ms. Priya Gandhi to INR 10 lakh per month, rectifying a typographical error in the notice for its 39th Annual General Meeting (AGM). The company stated that the remuneration terms approved by the Board of Directors specified INR 10 lakh per month, whereas the explanatory statement in the AGM notice had incorrectly listed the figure as INR 8.40 lakh per month. The AGM is scheduled to be held on Tuesday, 21 July 2026 at 10:30 a.m. (IST) through Video Conference or Other Audio Visual Means.

The corrigendum, submitted to BSE Limited and National Stock Exchange of India Limited, clarifies that the adjustment is solely to rectify the clerical error and does not represent a change in the approved remuneration policy. The revised figure will be presented to shareholders for approval as part of the special resolution regarding the re-appointment of Ms. Priya Gandhi for a period of three years commencing from 28 October 2026 to 27 October 2029.

AGM Agenda and Resolutions

The 39th AGM will transact ordinary and special business, including the adoption of audited standalone and consolidated financial statements for the financial year ended 31 March 2026. The Board has recommended a dividend of INR 11 per equity share of INR 10 each fully paid-up for the financial year ended 31 March 2026. Additionally, shareholders will vote on the ratification of the remuneration for Cost Auditor Kiran J. Mehta & Co., set at up to INR 0.25 million plus goods and service tax and reimbursement of out-of-pocket expenses for the financial year ending 31 March 2027.

Executive Director Re-appointment

Ms. Priya Gandhi, who has served as Executive Director since October 2021, is proposed for re-appointment. Her remuneration package includes a gross salary of INR 10 lakh per month, perquisites such as housing, medical expenses, and club memberships, and contributions to provident and superannuation funds. The aggregate remuneration and perquisites in any financial year will not exceed the limits prescribed under the Companies Act, 2013.

Financial Performance

The company reported a net profit after tax of INR 521 million for the financial year 2025-26, compared to INR 318.42 million in the previous year. Total income for the period stood at INR 2,997.71 million. The Board noted that the company has been consistently profitable and expects to continue this trend through capacity utilisation and productivity improvements.

Hester Biosciences Limited has fixed Tuesday, 14 July 2026 as the record date to determine shareholders eligible for the final dividend of ₹11 per equity share and for e-voting at its upcoming Annual General Meeting. The dividend, equivalent to 110% of the face value of ₹10 each, is subject to approval at the 39th AGM and deduction of applicable tax. This announcement follows the company's financial results for the year ended 31 March 2026, which highlighted a strong recovery in profitability.

The company reported a 64% increase in standalone profit after tax to ₹521.00 million for FY26, up from ₹318.42 million in the previous year. Consolidated profit after tax surged 99% to ₹574.84 million from ₹288.26 million in the prior year. Standalone revenue from operations for FY26 stood at ₹2,921.36 million, a 2% increase from ₹2,864.66 million, while consolidated revenue grew 7% to ₹3,325.99 million from ₹3,111.02 million.

The Board of Directors has recommended the final dividend amounting to ₹93.58 million, reflecting a payout ratio of 18% of standalone profits. The payment is scheduled on or after Tuesday, 28 July 2026. The company’s EBITDA increased by 56% to ₹871.03 million from ₹557.08 million, while the debt-equity ratio improved to 0.19 from 0.31 on a standalone basis.

Financial Performance

The following table summarizes the company’s financial performance for the year ended 31 March 2026:

Operational Highlights

The Poultry Healthcare division drove growth, recording a 24% increase in revenue. The Animal Healthcare segment faced challenges due to delays in government-led immunisation programmes. The company capitalised its Fill-Finish and BSL-3 facilities during the year to enhance manufacturing capabilities. It also received marketing and manufacturing licences for its H9N2 low pathogenic Avian Influenza vaccine and undertook a partial divestment of its stake in Texas Lifesciences Private Limited, reducing its holding from 54.81% to 11%.

Corporate Governance

The 39th Annual General Meeting is scheduled for Tuesday, 21 July 2026, at 10:30 AM (IST) via Video Conferencing. Shareholders can participate in remote e-voting from 9:00 a.m. (IST) on Saturday, 18 July 2026, to 5:00 p.m. (IST) on Monday, 20 July 2026.